AAAAAA
Results:
1-15
|
Results: 15
Authors:
Eisenhauer, EA
Citation: Ea. Eisenhauer, From the molecule to the clinic - inhibiting HER2 to treat breast cancer., N ENG J MED, 344(11), 2001, pp. 841-842
Authors:
Therasse, P
Arbuck, SG
Eisenhauer, EA
Wanders, J
Kaplan, RS
Rubinstein, L
Verweij, J
Van Glabbeke, M
van Oosterom, AT
Christian, MC
Gwyther, SG
Citation: P. Therasse et al., New guidelines to evaluate the response to treatment in solid Tumors, J NAT CANC, 92(3), 2000, pp. 205-216
Authors:
Vergote, I
Rustin, GJS
Eisenhauer, EA
Kristensen, GB
Pujade-Lauraine, E
Parmar, MKB
Friedlander, M
Jakobsen, A
Vermorken, JB
Citation: I. Vergote et al., Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer], J NAT CANC, 92(18), 2000, pp. 1534-1535
Authors:
Eisenhauer, EA
Citation: Ea. Eisenhauer, New cytotoxics and non-cytotoxics in epithelial ovarian cancer, INT J GYN C, 10, 2000, pp. 38-43
Authors:
Eisenhauer, EA
O'Dwyer, PJ
Christian, M
Humphrey, JS
Citation: Ea. Eisenhauer et al., Phase I clinical trial design in cancer drug development, J CL ONCOL, 18(3), 2000, pp. 684-692
Phase I and II evaluation of novel anticancer agents: Are response and toxicity the right endpoints?
Authors:
Eisenhauer, EA
Citation: Ea. Eisenhauer, Phase I and II evaluation of novel anticancer agents: Are response and toxicity the right endpoints?, ONKOLOGIE, 23, 2000, pp. 2-6
Authors:
Gelmon, KA
Eisenhauer, EA
Harris, AL
Ratain, MJ
Workman, P
Citation: Ka. Gelmon et al., Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development?, J NAT CANC, 91(15), 1999, pp. 1281-1287
Authors:
MacNeil, M
Eisenhauer, EA
Citation: M. Macneil et Ea. Eisenhauer, High-dose chemotherapy: Is it standard management for any common solid tumor?, ANN ONCOL, 10(10), 1999, pp. 1145-1161
Authors:
Cripps, C
Burnell, M
Jolivet, J
Batist, G
Lofters, W
Dancey, J
Iglesias, J
Fisher, B
Eisenhauer, EA
Citation: C. Cripps et al., Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC ClinicalTrials Group study, ANN ONCOL, 10(10), 1999, pp. 1175-1179
Authors:
Eisenhauer, EA
Gore, M
Neijt, JP
Citation: Ea. Eisenhauer et al., Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner?, ANN ONCOL, 10, 1999, pp. 9-15
Authors:
Kaye, SB
Eisenhauer, EA
Hamilton, TC
Citation: Sb. Kaye et al., New non-cytotoxic approaches to ovarian cancer, ANN ONCOL, 10, 1999, pp. 65-68
Authors:
Piccart, MJ
Stuart, GCE
Cassidy, J
Bertelsen, K
Parmar, MKB
Eisenhauer, EA
Kaye, SB
Trope, C
Swenerton, K
Harper, P
Vermorken, JB
Citation: Mj. Piccart et al., Intergroup collaboration in ovarian cancer: a giant step forward, ANN ONCOL, 10, 1999, pp. 83-86
Authors:
Berek, JS
Bertelsen, K
du Bois, A
Brady, MF
Carmichael, J
Eisenhauer, EA
Gore, M
Grenman, S
Hamilton, TC
Hansen, SW
Harper, PG
Horvath, G
Kaye, SB
Luck, HJ
Lund, B
McGuire, WP
Neijt, JP
Ozols, RF
Parmar, MKB
Piccart-Gebhart, MJ
van Rijswijk, R
Rosenberg, P
Rustin, GJS
Sessa, C
Thigpen, JT
Trope, C
Tuxen, MK
Vergote, I
Vermorken, JB
Willemse, PHB
Citation: Js. Berek et al., Advanced epithelial ovarian cancer: 1998 consensus statements, ANN ONCOL, 10, 1999, pp. 87-92
Authors:
Hospers, GAP
Eisenhauer, EA
de Vries, EGE
Citation: Gap. Hospers et al., The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects, BR J CANC, 80(5-6), 1999, pp. 629-638
Authors:
Eisenhauer, EA
Citation: Ea. Eisenhauer, New drugs and new approaches including inhibitors of invasion, EUROCANCER 98, 1998, pp. 247-248
Risultati:
1-15
|